Inventor
WEST JAMES WILLIAM
US34 patents
⚠️ This page may combine multiple inventors who share the name “WEST JAMES WILLIAM”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
CYTOMX THERAPEUTICS INC
30 patentsUS9127053B2Sep 8, 2015
Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof
CYTOMX THERAPEUTICS INC39 citations97
US9120853B2Sep 1, 2015
Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
CYTOMX THERAPEUTICS INC52 citations97
US10118961B2Nov 6, 2018
Modified antibody containing the cleavable peptide with the amino acid sequence TGRGPSWV
CYTOMX THERAPEUTICS INC34 citations96
US10059762B2Aug 28, 2018
Anti-EGFR activatable antibodies
CYTOMX THERAPEUTICS INC42 citations95
US10745481B2Aug 18, 2020
Anti-CD166 antibodies, activatable anti-CD166 antibodies, and methods of use thereof
CYTOMX THERAPEUTICS INC22 citations94
US10301380B2May 28, 2019
Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof
CYTOMX THERAPEUTICS INC17 citations94
US9889211B2Feb 13, 2018
Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
CYTOMX THERAPEUTICS INC29 citations94
US10336824B2Jul 2, 2019
Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of thereof
CYTOMX THERAPEUTICS INC16 citations93
US9309510B2Apr 12, 2016
Protease-resistant systems for polypeptide display and methods of making and using thereof
CYTOMX THERAPEUTICS INC26 citations93
US10875913B2Dec 29, 2020
Methods of treatment using activatable anti-EGFR antibodies
CYTOMX THERAPEUTICS INC21 citations92
US9545442B2Jan 17, 2017
Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
CYTOMX THERAPEUTICS INC19 citations92
US9487590B2Nov 8, 2016
Activatable antibodies that bind interleukin-6 receptor and methods of use thereof
CYTOMX THERAPEUTICS INC15 citations92
US10513558B2Dec 24, 2019
Anti-PD1 antibodies, activatable anti-PD1 antibodies, and methods of use thereof
CYTOMX THERAPEUTICS INC23 citations89
US11753466B2Sep 12, 2023
Anti-CD166 antibodies, activatable anti-CD166 antibodies, and methods of use thereof
CYTOMX THERAPEUTICS INC7 citations85
US11046759B2Jun 29, 2021
Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereof
CYTOMX THERAPEUTICS INC4 citations84
US10709799B2Jul 14, 2020
Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
CYTOMX THERAPEUTICS INC10 citations84
US9688748B2Jun 27, 2017
Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof
CYTOMX THERAPEUTICS INC11 citations84
US10669339B2Jun 2, 2020
Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof
CYTOMX THERAPEUTICS INC10 citations83
US11161906B2Nov 2, 2021
Multispecific antibodies, multispecific activatable antibodies and methods of using the same
CYTOMX THERAPEUTICS INC12 citations82
US11890354B2Feb 6, 2024
Activatable antibodies that bind epidermal growth factor receptor and methods thereof
CYTOMX THERAPEUTICS INC2 citations73
US11174316B2Nov 16, 2021
Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof
CYTOMX THERAPEUTICS INC1 citations72
US10611845B2Apr 7, 2020
Activatable antibodies that bind interleukin-6 receptor and methods of use thereof
CYTOMX THERAPEUTICS INC2 citations72
US12502439B2Dec 23, 2025
Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
CYTOMX THERAPEUTICS INC0 citations62
US12459999B2Nov 4, 2025
Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereof
CYTOMX THERAPEUTICS INC0 citations62
US12139816B2Nov 12, 2024
Protease-resistant systems for polypeptide display and methods of making and using thereof
CYTOMX THERAPEUTICS INC0 citations62
US11548943B2Jan 10, 2023
Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereof
CYTOMX THERAPEUTICS INC0 citations62
US11548944B2Jan 10, 2023
Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereof
CYTOMX THERAPEUTICS INC0 citations62
US11472875B1Oct 18, 2022
Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereof
CYTOMX THERAPEUTICS INC0 citations62
US11198864B2Dec 14, 2021
Protease-resistant systems for polypeptide display and methods of making and using thereof
CYTOMX THERAPEUTICS INC0 citations62
US10947531B2Mar 16, 2021
Protease-resistant systems for polypeptide display and methods of making and using thereof
CYTOMX THERAPEUTICS INC0 citations62
BRISTOL MYERS SQUIBB CO
4 patentsUS11117968B2Sep 14, 2021
Activatable anti-CTLA-4 antibodies and uses thereof
BRISTOL MYERS SQUIBB CO2 citations69
US11952427B2Apr 9, 2024
Anti-CD40 antibodies and uses thereof
BRISTOL MYERS SQUIBB CO0 citations61
US11306149B2Apr 19, 2022
Anti-CD40 antibodies and uses thereof
BRISTOL MYERS SQUIBB CO1 citations61
US12441799B2Oct 14, 2025
Activatable anti-CTLA-4 antibodies and uses thereof
BRISTOL MYERS SQUIBB CO1 citations60